GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Progyny Inc (NAS:PGNY) » Definitions » Cash, Cash Equivalents, Marketable Securities

Progyny (Progyny) Cash, Cash Equivalents, Marketable Securities

: $371 Mil (As of Dec. 2023)
View and export this data going back to 2019. Start your Free Trial

Progyny's quarterly cash, cash equivalents, marketable securities increased from Jun. 2023 ($282.50 Mil) to Sep. 2023 ($335.55 Mil) and increased from Sep. 2023 ($335.55 Mil) to Dec. 2023 ($371.09 Mil).

Progyny's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($119.42 Mil) to Dec. 2022 ($189.30 Mil) and increased from Dec. 2022 ($189.30 Mil) to Dec. 2023 ($371.09 Mil).


Progyny Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Progyny's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progyny Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Premium Member Only Premium Member Only 80.38 109.30 119.42 189.30 371.09

Progyny Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash, Cash Equivalents, Marketable Securities Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 189.30 207.89 282.50 335.55 371.09

Progyny Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Progyny  (NAS:PGNY) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Progyny Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Progyny's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Progyny (Progyny) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1359 Broadway, New York, NY, USA, 10018
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
Executives
David J Schlanger director, officer: Executive Chairman C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Michael E Sturmer officer: President 48 LEDYARD RD, WEST HARTFORD CT 06117
Mark S. Livingston officer: Chief Financial Officer C/O PROGYNY, INC., 1359 BROADWAY, 2ND FL, NEW YORK NY 10018
Kevin K Gordon director 155 S LIMERICK RD, LIMERICK PA 19468
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Peter Anevski officer: Chief Executive Officer C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK NY 10018
Cheryl Scott director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Norman Payson director 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203
Allison Swartz officer: EVP, GC C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Lloyd H Dean director 185 BERRY STREET, SUITE 300, SAN FRANCISCO CA 94107
Monice Barbero officer: EVP, GC and Secretary C/O PROGYNY, INC., 1359 BROADWAY, NEW YORK NY 10018
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Beth C Seidenberg director
Jennifer Bealer officer: EVP, General Counsel C/O PROGYNY, INC., 245 5TH AVENUE, NEW YORK NY 10016
Malissia Clinton director 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730